We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCHI icon
151
iShares MSCI China ETF
MCHI
$6.04B
$167K ﹤0.01%
4,100
– –
AMRX icon
152
Amneal Pharmaceuticals
AMRX
$5.72B
$155K ﹤0.01%
+25,470
New +$113K
THC icon
153
Tenet Healthcare
THC
$20.1B
$109K ﹤0.01%
1,447
+747
+107% +$47.4K
A icon
154
Agilent Technologies
A
$39.1B
$50.5K ﹤0.01%
+363
New +$43.2K
QCOM icon
155
Qualcomm
QCOM
$176B
$50.2K ﹤0.01%
+347
New +$43K
NVDA icon
156
NVIDIA
NVDA
$5.01T
$49K ﹤0.01%
+990
New +$45.9K
ORCL icon
157
Oracle
ORCL
$331B
$47.9K ﹤0.01%
+454
New +$49.5K
MSFT icon
158
Microsoft
MSFT
$2.84T
$45.9K ﹤0.01%
+122
New +$43.4K
MTD icon
159
Mettler-Toledo International
MTD
$26.8B
$30.3K ﹤0.01%
+25
New +$27K
EXAI
160
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$11.3K ﹤0.01%
+1,765
New +$10K
IONQ icon
161
IonQ
IONQ
$12.3B
$9.18K ﹤0.01%
+741
New +$9.55K
AKRO
162
DELISTED
Akero Therapeutics
AKRO
– –
-25,000
Closed -$1.26M
AMED
163
DELISTED
Amedisys
AMED
– –
-106,387
Closed -$9.94M
ASR icon
164
Grupo Aeroportuario del Sureste
ASR
$8.03B
– –
-135
Closed -$165
DGX icon
165
Quest Diagnostics
DGX
$25.1B
– –
-1,324
Closed -$161K
EQIX icon
166
Equinix
EQIX
$107B
– –
-40
Closed -$29.1K
EVTC icon
167
Evertec
EVTC
$1.83B
– –
-739
Closed -$27.5K
GH icon
168
Guardant Health
GH
$19.5B
– –
-74,525
Closed -$2.21M
INFY icon
169
Infosys
INFY
$45B
– –
-1,130
Closed -$19.6K
JAZZ icon
170
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-266,226
Closed -$34.5M
MRSN
171
DELISTED
Mersana Therapeutics
MRSN
– –
-208,745
Closed -$6.63M
SEER icon
172
Seer Inc
SEER
$108M
– –
-123,426
Closed -$273K
TSM icon
173
TSMC
TSM
$2.09T
– –
-1,089
Closed -$1.96K
UMC icon
174
United Microelectronic
UMC
$48.9B
– –
-2,698
Closed -$18.9K
VTYX
175
DELISTED
Ventyx Biosciences
VTYX
– –
-24,500
Closed -$851K
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.